New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibro...
Ingelheim, Germany, 22 September 2011 – Phase II clinical trial results, published today in the New England Journal of Medicine, for Boehringer Ingelheim’s investigational tyrosine kinase inhibitor (TKI) BIBF 1120* showed a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF). 1 IPF is a chronic, progressive, severely debilitating lung disease with a high mortality rate, for which there are limited treatment options. 2
